What is the current In Vivo and In Vitro ADME and PK market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the In Vivo and In Vitro ADME and PK market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the In Vivo and In Vitro ADME and PK market?

Increasing demand for toxicology testing and rising awareness of drug safety.

What are the major challenges facing the In Vivo and In Vitro ADME and PK market?

High costs associated with testing and stringent regulatory requirements.

Which regions are expected to lead the In Vivo and In Vitro ADME and PK market?

North America and Europe are expected to dominate the market.

Who are the top companies in the In Vivo and In Vitro ADME and PK market?

Leading companies include Thermo Fisher and Charles River Laboratories.

What future opportunities exist in the In Vivo and In Vitro ADME and PK market?

Emerging technologies and growing demand in Asia-Pacific present opportunities.

How will technology impact the In Vivo and In Vitro ADME and PK market future outlook?

Advances in automation and AI will improve efficiency and accuracy.

What is the current regulatory landscape for the In Vivo and In Vitro ADME and PK market?

Regulations are becoming more stringent, driving demand for compliant services.

Why Is the In Vivo and In Vitro ADME and PK Market Growing So Fast? 2026 Analysis

In Vivo and In Vitro ADME and PK by Application (Biopharmaceutical Companies, Government and Academic Institutes, Others), by Types (Small Molecules, Biologics), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

In Vivo and In Vitro ADME and PK Market Overview

The In Vivo and In Vitro ADME and PK market refers to the research and analysis of absorption, distribution, metabolism, and excretion, as well as pharmacokinetics, in living organisms and laboratory settings. As the In Vivo and In Vitro ADME and PK market size is estimated to be around $8.5 billion, the growth outlook for this industry is promising, with a market forecast indicating significant expansion over the next few years. The industry expansion is driven by the increasing demand for efficient and accurate drug development processes, with the global market expected to grow at a CAGR of 7.5% during the forecast period. Key drivers of this growth include advances in technology, stringent regulatory requirements, and the need for more effective and safe drugs.

Loading chart…

The In Vivo and In Vitro ADME and PK market is shaped by several key forces, including technology shifts, such as the adoption of microfluidics and 3D cell culture systems, regulations, such as those related to drug safety and efficacy, and consumer behavior, such as the increasing demand for personalized medicine. The largest region in this market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the increasing investments in pharmaceutical research and development in countries such as China and India. As the market continues to evolve, it is essential for industry players to stay ahead of the curve and adapt to the changing landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	23.67 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Charles River; Labcorp; ICON; Syneos Health; Envigo; Curia; Evotec; Bioduro-Sundia; Lonza; WuXi AppTec; IQVIA; Tecan Group; Pharmaron; Shanghai Medicilon; ChemPartner; Joinn Laboratories; RTI International; Eurofins Scientific; Aragen Life Sciences; Sai Life Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The In Vivo and In Vitro ADME and PK market is poised for significant growth, driven by factors that are transforming the pharmaceutical and biotechnology industries. Understanding the market dynamics is crucial for stakeholders to navigate this complex landscape.

Growth Drivers2 items

Increasing demand for personalized medicine is driving the need for more accurate and efficient ADME and PK studies, thereby contributing to the growth of the In Vivo and In Vitro ADME and PK market size.

Advancements in high-throughput screening technologies are enabling faster and more cost-effective drug discovery processes, fueling the growth forecast of the In Vivo and In Vitro ADME and PK market.

Restraints2 items

The high cost of in vivo studies, including the cost of animal models and maintenance, is a significant restraint on the growth of the In Vivo and In Vitro ADME and PK market, as it limits the adoption of these studies among smaller pharmaceutical and biotechnology companies.

Stringent regulatory requirements for the conduct of ADME and PK studies, including the need for specialized facilities and personnel, can hinder the growth of the In Vivo and In Vitro ADME and PK market size, particularly for new market entrants.

Opportunities2 items

The growing trend towards outsourcing ADME and PK studies to contract research organizations (CROs) presents opportunities for the In Vivo and In Vitro ADME and PK market to expand its reach and capabilities, particularly in emerging markets.

The development of novel in vitro models, such as 3D cell cultures and organ-on-a-chip systems, offers opportunities for the In Vivo and In Vitro ADME and PK market to improve the accuracy and efficiency of drug discovery and development processes.

Challenges2 items

The integration of artificial intelligence and machine learning into ADME and PK studies poses a challenge for the In Vivo and In Vitro ADME and PK market, as it requires significant investments in data management and analytics infrastructure.

The need to balance drug efficacy and safety in the context of ADME and PK studies is a significant challenge for the In Vivo and In Vitro ADME and PK market, as it requires careful consideration of complex pharmacokinetic and pharmacodynamic relationships.

Market Segmentation

Loading chart…

The In Vivo ADME and PK market can be segmented based on application and types. The application segment includes subtypes such as pharmacokinetics, pharmacodynamics, and toxicology. These subtypes contribute to the overall market size by providing valuable insights into the absorption, distribution, metabolism, and excretion of drugs in living organisms. The types segment includes subtypes such as preclinical and clinical trials, which are crucial for determining the efficacy and safety of drugs.

The In Vitro ADME and PK market can also be segmented based on application and types. The application segment includes subtypes such as drug discovery, drug development, and quality control. These subtypes contribute to the overall market size by providing high-throughput screening and testing of drugs in a controlled laboratory setting. Understanding the In Vivo and In Vitro ADME and PK segmentation is essential for market players to identify opportunities and challenges in the industry.

In Vivo and In Vitro ADME and PK Segmentation Breakdown7 items

Application

Biopharmaceutical Companies

Government and Academic Institutes

Others

Types

Small Molecules

Biologics

Regional Insights

Loading chart…

The In Vivo and In Vitro ADME and PK market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing investments in pharmaceutical research and development, a growing demand for efficient drug discovery processes, and government initiatives to support the growth of the biotechnology sector.

Key drivers for each region include: for North America, adoption of advanced technologies, favorable policies and regulations, and a mature ecosystem; for Europe, increasing investments in research and development, a strong infrastructure for pharmaceutical manufacturing, and a highly skilled workforce; for Asia Pacific, growing demographics and an expanding middle class, increasing adoption of in vivo and in vitro testing, and government support for the biotechnology industry; for Latin America, rising demand for pharmaceuticals, improving infrastructure, and a growing ecosystem for biotechnology research; and for Middle East & Africa, increasing investments in healthcare, a growing demand for pharmaceuticals, and a developing ecosystem for biotechnology research.

The regional forecast indicates that the Asia Pacific region will experience the highest growth rate, driven by the factors mentioned above. In contrast, the Middle East & Africa region is expected to have a relatively lower share of the market, but still offers opportunities for growth due to its developing healthcare sector and increasing demand for pharmaceuticals.

Competitive Landscape

The In Vivo and In Vitro ADME and PK competitive landscape is moderately consolidated, with a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by a combination of global players with extensive resources and local companies with strong regional ties, leading to a complex In Vivo and In Vitro ADME and PK competitive landscape.

Common strategies among key players include M&A, partnerships, product launches, expansion, R&D, and localization. Companies differentiate themselves through technology, service model, channel strength, customization, and cost advantages. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting their strategies to stay competitive.

Charles River: regional expansion

Labcorp: vertical integration

ICON: premium pricing

Syneos Health: OEM tie-ups

Envigo: innovation pipeline

Curia: local manufacturing

Key In Vivo and In Vitro ADME and PK Companies20 items

Charles River

Labcorp

ICON

Syneos Health

Envigo

Curia

Evotec

Bioduro-Sundia

Lonza

WuXi AppTec

IQVIA

Tecan Group

Pharmaron

Shanghai Medicilon

ChemPartner

Joinn Laboratories

RTI International

Eurofins Scientific

Aragen Life Sciences

Sai Life Sciences

Market Ecosystem

The In Vivo and In Vitro ADME and PK ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. Value is created and captured through the development, integration, and application of ADME and PK technologies, with various stakeholders influencing the flow of value across the ecosystem. The ecosystem can be broadly segmented into three tiers: upstream technology providers and suppliers, midstream integrators and channels, and downstream end users.

Raw material/component suppliers — provide essential materials

Technology providers — develop ADME and PK technologies

System integrators / EPCs — integrate technologies into solutions

Distributors / channel partners — deliver solutions to end users

Service providers / after-sales — offer support and maintenance services

End users / buyers — apply ADME and PK technologies in research and development

Regulators/standards bodies — establish guidelines and standards for ADME and PK practices

The flow of value across the In Vivo and In Vitro ADME and PK ecosystem is influenced by various control points, including regulatory bodies, technology providers, and end users. Dependency risks, such as input constraints, standards, and approvals, can impact the adoption and application of ADME and PK technologies. Switching costs, partnerships, and interoperability requirements also play a crucial role in shaping the ecosystem, with different regions exhibiting distinct characteristics due to variations in regulatory frameworks, market demand, and technological advancements. A thorough value chain analysis is essential to understand the intricacies of the In Vivo and In Vitro ADME and PK ecosystem and identify opportunities for growth and innovation.

Recent Industry Insights

The In Vivo and In Vitro ADME and PK industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between major pharmaceutical companies and contract research organizations, have accelerated the growth of the market. Additionally, there have been notable mergers and acquisitions, with companies seeking to expand their capabilities in in vivo and in vitro testing.

The market has also seen the launch of innovative products and technologies, including advanced in vitro systems and imaging technologies. Furthermore, regulatory changes, such as updated guidelines for ADME and PK studies, have influenced the industry landscape. A shift in consumer and enterprise trends towards more efficient and cost-effective testing methods has also driven the demand for in vivo and in vitro services, with several companies securing funding rounds or expansions to meet this growing demand.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the In Vivo and In Vitro ADME and PK market. The market attractiveness is high, driven by increasing demand for innovative and efficient drug development processes. The competitive intensity is moderate, with key players focusing on strategic partnerships and investments in research and development. The long-term In Vivo and In Vitro ADME and PK market outlook is promising, with a growing need for personalized medicine and targeted therapies.

The innovation landscape is evolving, with advancements in technologies such as microfluidics and 3D cell cultures. The demand-supply balance is expected to be stable, with a steady growth in demand met by increasing supply from emerging players. However, key risk factors include regulatory changes and high research and development costs. Overall, the market presents opportunities for growth and investment, driven by the need for efficient and effective drug development processes.

11 items

1. Executive Summary

2. In Vivo and In Vitro ADME and PK Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global In Vivo and In Vitro ADME and PK Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global In Vivo and In Vitro ADME and PK Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Biopharmaceutical Companies

6.1.2. Government and Academic Institutes

6.1.3. Others

6.2. Global In Vivo and In Vitro ADME and PK Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Small Molecules

6.2.2. Biologics

6.3. Global In Vivo and In Vitro ADME and PK Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global In Vivo and In Vitro ADME and PK Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global In Vivo and In Vitro ADME and PK Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global In Vivo and In Vitro ADME and PK Market Competition by Key Manufacturers

8.1. Global In Vivo and In Vitro ADME and PK Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global In Vivo and In Vitro ADME and PK: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Charles River

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Labcorp

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. ICON

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Syneos Health

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Envigo

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Curia

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Evotec

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bioduro-Sundia

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Lonza

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. WuXi AppTec

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. IQVIA

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Tecan Group

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Pharmaron

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Shanghai Medicilon

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. ChemPartner

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Joinn Laboratories

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. RTI International

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Eurofins Scientific

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Aragen Life Sciences

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Sai Life Sciences

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global In Vivo and In Vitro ADME and PK Market

Figure 4: Global In Vivo and In Vitro ADME and PK Market: Drivers

Figure 5: Global In Vivo and In Vitro ADME and PK Market: Challenges

Figure 6: Global In Vivo and In Vitro ADME and PK Market: Trends

Figure 7: Global In Vivo and In Vitro ADME and PK Market: Opportunity

Figure 8: Global In Vivo and In Vitro ADME and PK Market: Restraint

Figure 9: Global In Vivo and In Vitro ADME and PK Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global In Vivo and In Vitro ADME and PK Market Value (USD Million) By Region

Figure 15: Global In Vivo and In Vitro ADME and PK Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global In Vivo and In Vitro ADME and PK Market Value (USD Million) By Region

Figure 23: Global In Vivo and In Vitro ADME and PK Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global In Vivo and In Vitro ADME and PK Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global In Vivo and In Vitro ADME and PK Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global In Vivo and In Vitro ADME and PK Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global In Vivo and In Vitro ADME and PK Market Value (USD Million) By Region

Table 10: Global In Vivo and In Vitro ADME and PK Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global In Vivo and In Vitro ADME and PK Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global In Vivo and In Vitro ADME and PK Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global In Vivo and In Vitro ADME and PK Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Charles River Basic Information And Sales Area

Table 31: Charles River. Products Portfolio

Table 32: Labcorp Basic Information And Sales Area

Table 33: Labcorp. Products Portfolio

Table 34: ICON Basic Information And Sales Area

Table 35: ICON. Products Portfolio

Table 36: Syneos Health Basic Information And Sales Area

Table 37: Syneos Health. Products Portfolio

Table 38: Envigo Basic Information And Sales Area

Table 39: Envigo. Products Portfolio

Table 40: Curia Basic Information And Sales Area

Table 41: Curia. Products Portfolio

Table 42: Evotec Basic Information And Sales Area

Table 43: Evotec. Products Portfolio

Table 44: Bioduro-Sundia Basic Information And Sales Area

Table 45: Bioduro-Sundia. Products Portfolio

Table 46: Lonza Basic Information And Sales Area

Table 47: Lonza. Products Portfolio

Table 48: WuXi AppTec Basic Information And Sales Area

Table 49: WuXi AppTec. Products Portfolio

Table 50: IQVIA Basic Information And Sales Area

Table 51: IQVIA. Products Portfolio

Table 52: Tecan Group Basic Information And Sales Area

Table 53: Tecan Group. Products Portfolio

Table 54: Pharmaron Basic Information And Sales Area

Table 55: Pharmaron. Products Portfolio

Table 56: Shanghai Medicilon Basic Information And Sales Area

Table 57: Shanghai Medicilon. Products Portfolio

Table 58: ChemPartner Basic Information And Sales Area

Table 59: ChemPartner. Products Portfolio

Table 60: Joinn Laboratories Basic Information And Sales Area

Table 61: Joinn Laboratories. Products Portfolio

Table 62: RTI International Basic Information And Sales Area

Table 63: RTI International. Products Portfolio

Table 64: Eurofins Scientific Basic Information And Sales Area

Table 65: Eurofins Scientific. Products Portfolio

Table 66: Aragen Life Sciences Basic Information And Sales Area

Table 67: Aragen Life Sciences. Products Portfolio

Table 68: Sai Life Sciences Basic Information And Sales Area

Table 69: Sai Life Sciences. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global In Vivo and In Vitro ADME and PK Market Value (USD Million) By Region

Table 75: Global In Vivo and In Vitro ADME and PK Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

In Vivo and In Vitro ADME and PK Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	23.67 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Charles River; Labcorp; ICON; Syneos Health; Envigo; Curia; Evotec; Bioduro-Sundia; Lonza; WuXi AppTec; IQVIA; Tecan Group; Pharmaron; Shanghai Medicilon; ChemPartner; Joinn Laboratories; RTI International; Eurofins Scientific; Aragen Life Sciences; Sai Life Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

In Vivo and In Vitro ADME and PK Segmentation Breakdown7 items

Application

Biopharmaceutical Companies

Government and Academic Institutes

Others

Types

Small Molecules

Biologics

Regional Insights

Loading chart…

Competitive Landscape

Charles River: regional expansion

Labcorp: vertical integration

ICON: premium pricing

Syneos Health: OEM tie-ups

Envigo: innovation pipeline

Curia: local manufacturing

Key In Vivo and In Vitro ADME and PK Companies20 items

Charles River

Labcorp

ICON

Syneos Health

Envigo

Curia

Evotec

Bioduro-Sundia

Lonza

WuXi AppTec

IQVIA

Tecan Group

Pharmaron

Shanghai Medicilon

ChemPartner

Joinn Laboratories

RTI International

Eurofins Scientific

Aragen Life Sciences

Sai Life Sciences

Market Ecosystem

Raw material/component suppliers — provide essential materials

Technology providers — develop ADME and PK technologies

System integrators / EPCs — integrate technologies into solutions

Distributors / channel partners — deliver solutions to end users

Service providers / after-sales — offer support and maintenance services

End users / buyers — apply ADME and PK technologies in research and development

Regulators/standards bodies — establish guidelines and standards for ADME and PK practices

Recent Industry Insights

Analyst Overview

Table of Contents